An overview of Personalized Medicine landscape and policies in the European Union

Abstract Background The spread of Personalized Medicine (PM) over the last decade defined a revolution in healthcare systems. PM is among the priorities of the European Commission’s research agenda, which funded the IC2PerMed international project aiming to integrate China into the International Consortium of PM (ICPerMed). In the context of this project, we mapped the existing policies related to PM in the European Union (EU) and at the EU Member States (EU-MS) level. Methods PubMed, Google Scholar, Google, Microsoft and national and international institutions’ official repositories were searched in order to identify documents on PM-related policies, programmes and action plans at the EU and EU-MS level, published up to December 2020. Results We identified 28 policies in the EU aimed at improving public health promoting and fostering PM implementation, through some actions including the standardization of good medical practice, use of big data and digital innovation, data sharing and cross-border interoperability, healthcare sustainability, disease prevention and patients’/citizens’ engagement. We identified 23 policies at EU-MS level which, notwithstanding national differences, have a common focus, such as patient-tailored treatment and targeted prevention, education of healthcare workers, research and innovation, big data harmonization and healthcare system sustainability. Conclusions The definition of an integrated regulatory framework is essential to turn PM into an opportunity for citizens and patients with the involvement of all the stakeholders. This work can provide a valuable tool for decision-makers to define common approaches, priorities for research, development and increase international collaboration, which could overcome the fragmented European scenario and align the future direction on PM.

[1]  Andrea Mazzoni,et al.  Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives. , 2021, Personalized medicine.

[2]  A. Vicente,et al.  How personalised medicine will transform healthcare by 2030: the ICPerMed vision , 2020, Journal of Translational Medicine.

[3]  I. Norstedt,et al.  Personalized Medicine in Europe , 2017, Clinical and translational science.

[4]  David Cyranoski,et al.  China embraces precision medicine on a massive scale , 2016, Nature.

[5]  L. Looper A renewed vision for the pharmaceutical sector , 2014 .

[6]  Charles Auffray,et al.  Predictive, preventive, personalized and participatory medicine: back to the future , 2010, Genome Medicine.

[7]  A. Carrington,et al.  Regional Convergence in the European Union: A Stochastic Dominance Approach , 2006 .

[8]  Council conclusions on Health in the Digital Society — making progress in data-driven innovation in the field of health , 2017 .

[9]  Rhona K. M. Smith,et al.  Consolidated Version of the Treaty on the Functioning of the European Union , 2015 .

[10]  Council conclusions on personalised medicine for patients , 2015 .

[11]  Miek Peeters,et al.  Free movement of patients: Directive 2011/24 on the application of patients' rights in cross-border healthcare. , 2012, European journal of health law.

[12]  Christien Enzing,et al.  EU policies in personalized medicine-related technologies. , 2009, Personalized medicine.

[13]  COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS , 2009 .

[14]  Council conclusions on the " Reflection process on modern , responsive and sustainable health systems " , 2022 .